Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 30 entries
Sorted by: Best Match Show Resources per page
The 4-hydroxynonenal mediated oxidative damage of blood proteins and lipids involves secondary lipid peroxidation reactions.

Experimental and therapeutic medicine

Mustafa AG, Alfaqih MA, Al-Shboul O.
PMID: 30186450
Exp Ther Med. 2018 Sep;16(3):2132-2137. doi: 10.3892/etm.2018.6419. Epub 2018 Jul 06.

Lipid peroxidation is associated with several metabolic diseases. Lipid peroxidation causes cellular damage through reactive aldehyde species such as 4-hydroxyonenal (4-HNE). The exact mechanism(s) by which 4-HNE causes damage in the intravascular compartment is not yet exactly understood. Using...

Cite
Mustafa AG, Alfaqih MA, Al-Shboul O. The 4-hydroxynonenal mediated oxidative damage of blood proteins and lipids involves secondary lipid peroxidation reactions. Exp Ther Med. 2018;16(3):2132-2137doi: 10.3892/etm.2018.6419.
Mustafa, A. G., Alfaqih, M. A., & Al-Shboul, O. (2018). The 4-hydroxynonenal mediated oxidative damage of blood proteins and lipids involves secondary lipid peroxidation reactions. Experimental and therapeutic medicine, 16(3), 2132-2137. https://doi.org/10.3892/etm.2018.6419
Mustafa, Ayman G, et al. "The 4-hydroxynonenal mediated oxidative damage of blood proteins and lipids involves secondary lipid peroxidation reactions." Experimental and therapeutic medicine vol. 16,3 (2018): 2132-2137. doi: https://doi.org/10.3892/etm.2018.6419
Mustafa AG, Alfaqih MA, Al-Shboul O. The 4-hydroxynonenal mediated oxidative damage of blood proteins and lipids involves secondary lipid peroxidation reactions. Exp Ther Med. 2018 Sep;16(3):2132-2137. doi: 10.3892/etm.2018.6419. Epub 2018 Jul 06. PMID: 30186450; PMCID: PMC6122424.
Copy Download .nbib Format: NLM
Past, Present and Future Anti-Obesity Effects of Flavin-Containing and/or Copper-Containing Amine Oxidase Inhibitors.

Medicines (Basel, Switzerland)

Carpéné C, Boulet N, Chaplin A, Mercader J.
PMID: 30650583
Medicines (Basel). 2019 Jan 15;6(1). doi: 10.3390/medicines6010009.

No abstract available.

Cite
Carpéné C, Boulet N, Chaplin A, et al. Past, Present and Future Anti-Obesity Effects of Flavin-Containing and/or Copper-Containing Amine Oxidase Inhibitors. Medicines (Basel). 2019;6(1)doi: 10.3390/medicines6010009.
Carpéné, C., Boulet, N., Chaplin, A., & Mercader, J. (2019). Past, Present and Future Anti-Obesity Effects of Flavin-Containing and/or Copper-Containing Amine Oxidase Inhibitors. Medicines (Basel, Switzerland), 6(1), . https://doi.org/10.3390/medicines6010009
Carpéné, Christian, et al. "Past, Present and Future Anti-Obesity Effects of Flavin-Containing and/or Copper-Containing Amine Oxidase Inhibitors." Medicines (Basel, Switzerland) vol. 6,1 (2019). doi: https://doi.org/10.3390/medicines6010009
Carpéné C, Boulet N, Chaplin A, Mercader J. Past, Present and Future Anti-Obesity Effects of Flavin-Containing and/or Copper-Containing Amine Oxidase Inhibitors. Medicines (Basel). 2019 Jan 15;6(1). doi: 10.3390/medicines6010009. PMID: 30650583; PMCID: PMC6473341.
Copy Download .nbib Format: NLM
Transcranial magnetic stimulation-associated mania with psychosis: A case report.

The mental health clinician

Knox ED, Bota RG.
PMID: 34824963
Ment Health Clin. 2021 Nov 08;11(6):373-375. doi: 10.9740/mhc.2021.11.373. eCollection 2021 Nov.

Transcranial magnetic stimulation (TMS) is a noninvasive procedure used in the treatment of depression. We observed TMS-associated mania with psychotic symptoms in a 55-year-old male diagnosed with MDD and generalized anxiety disorder without history of psychosis or mania. Owing...

Cite
Knox ED, Bota RG. Transcranial magnetic stimulation-associated mania with psychosis: A case report. Ment Health Clin. 2021;11(6):373-375doi: 10.9740/mhc.2021.11.373.
Knox, E. D., & Bota, R. G. (2021). Transcranial magnetic stimulation-associated mania with psychosis: A case report. The mental health clinician, 11(6), 373-375. https://doi.org/10.9740/mhc.2021.11.373
Knox, Erin D, and Bota, Robert G. "Transcranial magnetic stimulation-associated mania with psychosis: A case report." The mental health clinician vol. 11,6 (2021): 373-375. doi: https://doi.org/10.9740/mhc.2021.11.373
Knox ED, Bota RG. Transcranial magnetic stimulation-associated mania with psychosis: A case report. Ment Health Clin. 2021 Nov 08;11(6):373-375. doi: 10.9740/mhc.2021.11.373. eCollection 2021 Nov. PMID: 34824963; PMCID: PMC8582772.
Copy Download .nbib Format: NLM
Opipramol Inhibits Lipolysis in Human Adipocytes without Altering Glucose Uptake and Differently from Antipsychotic and Antidepressant Drugs with Adverse Effects on Body Weight Control.

Pharmaceuticals (Basel, Switzerland)

Carpéné C, Les F, Mercader J, Gomez-Zorita S, Grolleau JL, Boulet N, Fontaine J, Iglesias-Osma MC, Garcia-Barrado MJ.
PMID: 32151075
Pharmaceuticals (Basel). 2020 Mar 05;13(3). doi: 10.3390/ph13030041.

Treatment with several antipsychotic drugs exhibits a tendency to induce weight gain and diabetic complications. The proposed mechanisms by which the atypical antipsychotic drug olanzapine increases body weight include central dysregulations leading to hyperphagia and direct peripheral impairment of...

Cite
Carpéné C, Les F, Mercader J, et al. Opipramol Inhibits Lipolysis in Human Adipocytes without Altering Glucose Uptake and Differently from Antipsychotic and Antidepressant Drugs with Adverse Effects on Body Weight Control. Pharmaceuticals (Basel). 2020;13(3)doi: 10.3390/ph13030041.
Carpéné, C., Les, F., Mercader, J., Gomez-Zorita, S., Grolleau, J. L., Boulet, N., Fontaine, J., Iglesias-Osma, M. C., & Garcia-Barrado, M. J. (2020). Opipramol Inhibits Lipolysis in Human Adipocytes without Altering Glucose Uptake and Differently from Antipsychotic and Antidepressant Drugs with Adverse Effects on Body Weight Control. Pharmaceuticals (Basel, Switzerland), 13(3), . https://doi.org/10.3390/ph13030041
Carpéné, Christian, et al. "Opipramol Inhibits Lipolysis in Human Adipocytes without Altering Glucose Uptake and Differently from Antipsychotic and Antidepressant Drugs with Adverse Effects on Body Weight Control." Pharmaceuticals (Basel, Switzerland) vol. 13,3 (2020). doi: https://doi.org/10.3390/ph13030041
Carpéné C, Les F, Mercader J, Gomez-Zorita S, Grolleau JL, Boulet N, Fontaine J, Iglesias-Osma MC, Garcia-Barrado MJ. Opipramol Inhibits Lipolysis in Human Adipocytes without Altering Glucose Uptake and Differently from Antipsychotic and Antidepressant Drugs with Adverse Effects on Body Weight Control. Pharmaceuticals (Basel). 2020 Mar 05;13(3). doi: 10.3390/ph13030041. PMID: 32151075; PMCID: PMC7151722.
Copy Download .nbib Format: NLM
Ligand-Promoted Iridium-Catalyzed Transfer Hydrogenation of Terminal Alkynes with Ethanol and Its Application.

ACS omega

Wang C, Gong S, Liang Z, Sun Y, Cheng R, Yang B, Liu Y, Yang J, Sun F.
PMID: 31592175
ACS Omega. 2019 Sep 18;4(14):16045-16051. doi: 10.1021/acsomega.9b02191. eCollection 2019 Oct 01.

A ligand-promoted iridium-catalyzed transfer hydrogenation of terminal alkynes with ethanol and its application has been developed. Highly chemical selectivity control is achieved based on ligand regulation. 1,2-Bis(diphenylphosphino)ethane was found to be critical for the transfer hydrogenation of alkynes. The...

Cite
Wang C, Gong S, Liang Z, et al. Ligand-Promoted Iridium-Catalyzed Transfer Hydrogenation of Terminal Alkynes with Ethanol and Its Application. ACS Omega. 2019;4(14):16045-16051doi: 10.1021/acsomega.9b02191.
Wang, C., Gong, S., Liang, Z., Sun, Y., Cheng, R., Yang, B., Liu, Y., Yang, J., & Sun, F. (2019). Ligand-Promoted Iridium-Catalyzed Transfer Hydrogenation of Terminal Alkynes with Ethanol and Its Application. ACS omega, 4(14), 16045-16051. https://doi.org/10.1021/acsomega.9b02191
Wang, Chengniu, et al. "Ligand-Promoted Iridium-Catalyzed Transfer Hydrogenation of Terminal Alkynes with Ethanol and Its Application." ACS omega vol. 4,14 (2019): 16045-16051. doi: https://doi.org/10.1021/acsomega.9b02191
Wang C, Gong S, Liang Z, Sun Y, Cheng R, Yang B, Liu Y, Yang J, Sun F. Ligand-Promoted Iridium-Catalyzed Transfer Hydrogenation of Terminal Alkynes with Ethanol and Its Application. ACS Omega. 2019 Sep 18;4(14):16045-16051. doi: 10.1021/acsomega.9b02191. eCollection 2019 Oct 01. PMID: 31592175; PMCID: PMC6777128.
Copy Download .nbib Format: NLM
Serotonin Syndrome following Introduction of Venlafaxine following Withdrawal of Phenelzine: Implications for Drug Washout Periods.

Therapeutic advances in psychopharmacology

Yates SJ, Ahuja N, Gartside SE, McAllister-Williams RH.
PMID: 23983936
Ther Adv Psychopharmacol. 2011 Aug;1(4):125-7. doi: 10.1177/2045125311413497.

No abstract available.

Cite
Yates SJ, Ahuja N, Gartside SE, et al. Serotonin Syndrome following Introduction of Venlafaxine following Withdrawal of Phenelzine: Implications for Drug Washout Periods. Ther Adv Psychopharmacol. 2011;1(4):125-7doi: 10.1177/2045125311413497.
Yates, S. J., Ahuja, N., Gartside, S. E., & McAllister-Williams, R. H. (2011). Serotonin Syndrome following Introduction of Venlafaxine following Withdrawal of Phenelzine: Implications for Drug Washout Periods. Therapeutic advances in psychopharmacology, 1(4), 125-7. https://doi.org/10.1177/2045125311413497
Yates, Sarah J, et al. "Serotonin Syndrome following Introduction of Venlafaxine following Withdrawal of Phenelzine: Implications for Drug Washout Periods." Therapeutic advances in psychopharmacology vol. 1,4 (2011): 125-7. doi: https://doi.org/10.1177/2045125311413497
Yates SJ, Ahuja N, Gartside SE, McAllister-Williams RH. Serotonin Syndrome following Introduction of Venlafaxine following Withdrawal of Phenelzine: Implications for Drug Washout Periods. Ther Adv Psychopharmacol. 2011 Aug;1(4):125-7. doi: 10.1177/2045125311413497. PMID: 23983936; PMCID: PMC3736920.
Copy Download .nbib Format: NLM
Comprehensive .

ACS pharmacology & translational science

Sacilotto N, Dessanti P, Lufino MMP, Ortega A, Rodríguez-Gimeno A, Salas J, Maes T, Buesa C, Mascaró C, Soliva R.
PMID: 34927013
ACS Pharmacol Transl Sci. 2021 Nov 12;4(6):1818-1834. doi: 10.1021/acsptsci.1c00223. eCollection 2021 Dec 10.

Lysine-specific demethylase 1 (LSD1 or KDM1A) is a chromatin modifying enzyme playing a key role in the cell cycle and cell differentiation and proliferation through the demethylation of histones and nonhistone substrates. In addition to its enzymatic activity, LSD1...

Cite
Sacilotto N, Dessanti P, Lufino MMP, et al. Comprehensive . ACS Pharmacol Transl Sci. 2021;4(6):1818-1834doi: 10.1021/acsptsci.1c00223.
Sacilotto, N., Dessanti, P., Lufino, M. M. P., Ortega, A., Rodríguez-Gimeno, A., Salas, J., Maes, T., Buesa, C., Mascaró, C., & Soliva, R. (2021). Comprehensive . ACS pharmacology & translational science, 4(6), 1818-1834. https://doi.org/10.1021/acsptsci.1c00223
Sacilotto, Natalia, et al. "Comprehensive ." ACS pharmacology & translational science vol. 4,6 (2021): 1818-1834. doi: https://doi.org/10.1021/acsptsci.1c00223
Sacilotto N, Dessanti P, Lufino MMP, Ortega A, Rodríguez-Gimeno A, Salas J, Maes T, Buesa C, Mascaró C, Soliva R. Comprehensive . ACS Pharmacol Transl Sci. 2021 Nov 12;4(6):1818-1834. doi: 10.1021/acsptsci.1c00223. eCollection 2021 Dec 10. PMID: 34927013; PMCID: PMC8669716.
Copy Download .nbib Format: NLM
Overview of the Neuroprotective Effects of the MAO-Inhibiting Antidepressant Phenelzine.

Cellular and molecular neurobiology

Matveychuk D, MacKenzie EM, Kumpula D, Song MS, Holt A, Kar S, Todd KG, Wood PL, Baker GB.
PMID: 33839994
Cell Mol Neurobiol. 2022 Jan;42(1):225-242. doi: 10.1007/s10571-021-01078-3. Epub 2021 Apr 10.

Phenelzine (PLZ) is a monoamine oxidase (MAO)-inhibiting antidepressant with anxiolytic properties. This multifaceted drug has a number of pharmacological and neurochemical effects in addition to inhibition of MAO, and findings on these effects have contributed to a body of...

Cite
Matveychuk D, MacKenzie EM, Kumpula D, et al. Overview of the Neuroprotective Effects of the MAO-Inhibiting Antidepressant Phenelzine. Cell Mol Neurobiol. 2021;42(1):225-242doi: 10.1007/s10571-021-01078-3.
Matveychuk, D., MacKenzie, E. M., Kumpula, D., Song, M. S., Holt, A., Kar, S., Todd, K. G., Wood, P. L., & Baker, G. B. (2022). Overview of the Neuroprotective Effects of the MAO-Inhibiting Antidepressant Phenelzine. Cellular and molecular neurobiology, 42(1), 225-242. https://doi.org/10.1007/s10571-021-01078-3
Matveychuk, Dmitriy, et al. "Overview of the Neuroprotective Effects of the MAO-Inhibiting Antidepressant Phenelzine." Cellular and molecular neurobiology vol. 42,1 (2022): 225-242. doi: https://doi.org/10.1007/s10571-021-01078-3
Matveychuk D, MacKenzie EM, Kumpula D, Song MS, Holt A, Kar S, Todd KG, Wood PL, Baker GB. Overview of the Neuroprotective Effects of the MAO-Inhibiting Antidepressant Phenelzine. Cell Mol Neurobiol. 2022 Jan;42(1):225-242. doi: 10.1007/s10571-021-01078-3. Epub 2021 Apr 10. PMID: 33839994.
Copy Download .nbib Format: NLM
The effect of antidepressive drugs and some related compounds on the levels of adenine nucleotides, inorganic phosphate and phosphocreatine in the rat brain.

British journal of pharmacology and chemotherapy

Lewis JJ, Van Petten GR.
PMID: 19108178
Br J Pharmacol Chemother. 1963 Jun;20(3):462-70. doi: 10.1111/j.1476-5381.1963.tb01483.x.

The effects upon levels of adenine nucleotides, phosphocreatine and inorganic phosphate of iproniazid, isoniazid, phenelzine, pheniprazine, tranylcypromine, harmine, imipramine, amitriptyline, orphenadrine, diphenhydramine and cocaine have been studied. With the exception of harmine and diphenhydramine, each of these compounds increased...

Cite
Lewis JJ, Van Petten GR. The effect of antidepressive drugs and some related compounds on the levels of adenine nucleotides, inorganic phosphate and phosphocreatine in the rat brain. Br J Pharmacol Chemother. 1963;20(3):462-70doi: 10.1111/j.1476-5381.1963.tb01483.x.
Lewis, J. J., & Van Petten, G. R. (1963). The effect of antidepressive drugs and some related compounds on the levels of adenine nucleotides, inorganic phosphate and phosphocreatine in the rat brain. British journal of pharmacology and chemotherapy, 20(3), 462-70. https://doi.org/10.1111/j.1476-5381.1963.tb01483.x
Lewis, J J, and Van Petten, G R. "The effect of antidepressive drugs and some related compounds on the levels of adenine nucleotides, inorganic phosphate and phosphocreatine in the rat brain." British journal of pharmacology and chemotherapy vol. 20,3 (1963): 462-70. doi: https://doi.org/10.1111/j.1476-5381.1963.tb01483.x
Lewis JJ, Van Petten GR. The effect of antidepressive drugs and some related compounds on the levels of adenine nucleotides, inorganic phosphate and phosphocreatine in the rat brain. Br J Pharmacol Chemother. 1963 Jun;20(3):462-70. doi: 10.1111/j.1476-5381.1963.tb01483.x. PMID: 19108178; PMCID: PMC1703802.
Copy Download .nbib Format: NLM
Antidepressants and inflammatory bowel disease: a systematic review.

Clinical practice and epidemiology in mental health : CP & EMH

Mikocka-Walus AA, Turnbull DA, Moulding NT, Wilson IG, Andrews JM, Holtmann GJ.
PMID: 16984660
Clin Pract Epidemiol Ment Health. 2006 Sep 20;2:24. doi: 10.1186/1745-0179-2-24.

BACKGROUND: A number of studies have suggested a link between the patient's psyche and the course of inflammatory bowel disease (IBD). Although pharmacotherapy with antidepressants has not been widely explored, some investigators have proposed that treating psychological co-morbidities with...

Cite
Mikocka-Walus AA, Turnbull DA, Moulding NT, et al. Antidepressants and inflammatory bowel disease: a systematic review. Clin Pract Epidemiol Ment Health. 2006;2:24doi: 10.1186/1745-0179-2-24.
Mikocka-Walus, A. A., Turnbull, D. A., Moulding, N. T., Wilson, I. G., Andrews, J. M., & Holtmann, G. J. (2006). Antidepressants and inflammatory bowel disease: a systematic review. Clinical practice and epidemiology in mental health : CP & EMH, 224. https://doi.org/10.1186/1745-0179-2-24
Mikocka-Walus, Antonina A, et al. "Antidepressants and inflammatory bowel disease: a systematic review." Clinical practice and epidemiology in mental health : CP & EMH vol. 2 (2006): 24. doi: https://doi.org/10.1186/1745-0179-2-24
Mikocka-Walus AA, Turnbull DA, Moulding NT, Wilson IG, Andrews JM, Holtmann GJ. Antidepressants and inflammatory bowel disease: a systematic review. Clin Pract Epidemiol Ment Health. 2006 Sep 20;2:24. doi: 10.1186/1745-0179-2-24. PMID: 16984660; PMCID: PMC1599716.
Copy Download .nbib Format: NLM
Scavenging of lipid peroxyl radicals protects plasma lipids and proteins from peroxynitrite.

Biomedical reports

Mustafa AG, Alfaqih MA, Al-Shboul O, Al-Dwairi A.
PMID: 30345039
Biomed Rep. 2018 Nov;9(5):421-426. doi: 10.3892/br.2018.1144. Epub 2018 Sep 07.

Peroxynitrite can be produced in the vasculature from a superoxide anion reaction with nitric oxide. A surplus of peroxynitrite in the intravascular compartment is a common feature of several chronic diseases. The development of pharmacological modalities that interfere with...

Cite
Mustafa AG, Alfaqih MA, Al-Shboul O, et al. Scavenging of lipid peroxyl radicals protects plasma lipids and proteins from peroxynitrite. Biomed Rep. 2018;9(5):421-426doi: 10.3892/br.2018.1144.
Mustafa, A. G., Alfaqih, M. A., Al-Shboul, O., & Al-Dwairi, A. (2018). Scavenging of lipid peroxyl radicals protects plasma lipids and proteins from peroxynitrite. Biomedical reports, 9(5), 421-426. https://doi.org/10.3892/br.2018.1144
Mustafa, Ayman G, et al. "Scavenging of lipid peroxyl radicals protects plasma lipids and proteins from peroxynitrite." Biomedical reports vol. 9,5 (2018): 421-426. doi: https://doi.org/10.3892/br.2018.1144
Mustafa AG, Alfaqih MA, Al-Shboul O, Al-Dwairi A. Scavenging of lipid peroxyl radicals protects plasma lipids and proteins from peroxynitrite. Biomed Rep. 2018 Nov;9(5):421-426. doi: 10.3892/br.2018.1144. Epub 2018 Sep 07. PMID: 30345039; PMCID: PMC6176101.
Copy Download .nbib Format: NLM
Administration of Supplemental L-Tyrosine with Phenelzine: A Clinical Literature Review [Expression of Concern].

Clinical pharmacology : advances and applications

[No authors listed]
PMID: 32425620
Clin Pharmacol. 2020 Apr 23;12:47. doi: 10.2147/CPAA.S240229. eCollection 2020.

No abstract available.

Cite
Administration of Supplemental L-Tyrosine with Phenelzine: A Clinical Literature Review [Expression of Concern]. Clin Pharmacol. 2020;12:47doi: 10.2147/CPAA.S240229.
(2020). Administration of Supplemental L-Tyrosine with Phenelzine: A Clinical Literature Review [Expression of Concern]. Clinical pharmacology : advances and applications, 1247. https://doi.org/10.2147/CPAA.S240229
"Administration of Supplemental L-Tyrosine with Phenelzine: A Clinical Literature Review [Expression of Concern]." Clinical pharmacology : advances and applications vol. 12 (2020): 47. doi: https://doi.org/10.2147/CPAA.S240229
Administration of Supplemental L-Tyrosine with Phenelzine: A Clinical Literature Review [Expression of Concern]. Clin Pharmacol. 2020 Apr 23;12:47. doi: 10.2147/CPAA.S240229. eCollection 2020. PMID: 32425620; PMCID: PMC7188510.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 30 entries